These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 19116277)

  • 21. Chebulagic acid from Terminalia chebula enhances insulin mediated glucose uptake in 3T3-L1 adipocytes via PPARγ signaling pathway.
    Shyni GL; Kavitha S; Indu S; Arya AD; Anusree SS; Vineetha VP; Vandana S; Sundaresan A; Raghu KG
    Biofactors; 2014; 40(6):646-57. PubMed ID: 25529897
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
    Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
    Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention.
    Kim MK; Chae YN; Kim HS; Choi SH; Son MH; Kim SH; Kim JK; Moon HS; Park SK; Shin YA; Kim JG; Lee CH; Lim JI; Shin CY
    Arch Pharm Res; 2009 May; 32(5):721-7. PubMed ID: 19471887
    [TBL] [Abstract][Full Text] [Related]  

  • 24. JTP-426467 acts as a selective antagonist for peroxisome proliferator-activated receptor gamma in vitro and in vivo.
    Nishiu J; Ito M; Ishida Y; Kakutani M; Shibata T; Matsushita M; Shindo M
    Diabetes Obes Metab; 2006 Sep; 8(5):508-16. PubMed ID: 16918585
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evolution of peroxisome proliferator-activated receptor agonists.
    Chang F; Jaber LA; Berlie HD; O'Connell MB
    Ann Pharmacother; 2007 Jun; 41(6):973-83. PubMed ID: 17519293
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Development of a cell-based peroxisome proliferator-activated receptors (PPARs) screening model and its application for evaluation of triterpenoids isolate from Alismatis Rhizoma].
    Li XY; Wang XH; Huang XQ; Wu TT; Xu W; Wu SS
    Zhongguo Zhong Yao Za Zhi; 2016 Nov; 41(21):4015-4022. PubMed ID: 28929690
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cilostazol ameliorates metabolic abnormalities with suppression of proinflammatory markers in a db/db mouse model of type 2 diabetes via activation of peroxisome proliferator-activated receptor gamma transcription.
    Park SY; Shin HK; Lee JH; Kim CD; Lee WS; Rhim BY; Hong KW
    J Pharmacol Exp Ther; 2009 May; 329(2):571-9. PubMed ID: 19221061
    [TBL] [Abstract][Full Text] [Related]  

  • 28. INT131: a selective modulator of PPAR gamma.
    Motani A; Wang Z; Weiszmann J; McGee LR; Lee G; Liu Q; Staunton J; Fang Z; Fuentes H; Lindstrom M; Liu J; Biermann DH; Jaen J; Walker NP; Learned RM; Chen JL; Li Y
    J Mol Biol; 2009 Mar; 386(5):1301-11. PubMed ID: 19452630
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Peroxisome proliferator-activated receptor {gamma} stimulation of adipocyte ApoE gene transcription mediated by the liver receptor X pathway.
    Yue L; Mazzone T
    J Biol Chem; 2009 Apr; 284(16):10453-61. PubMed ID: 19218241
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Benzimidazolones: a new class of selective peroxisome proliferator-activated receptor γ (PPARγ) modulators.
    Liu W; Lau F; Liu K; Wood HB; Zhou G; Chen Y; Li Y; Akiyama TE; Castriota G; Einstein M; Wang C; McCann ME; Doebber TW; Wu M; Chang CH; McNamara L; McKeever B; Mosley RT; Berger JP; Meinke PT
    J Med Chem; 2011 Dec; 54(24):8541-54. PubMed ID: 22070604
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Norlichexanthone isolated from fungus P16 promotes the secretion and expression of adiponectin in cultured ST-13 adipocytes.
    Ikeda M; Kurotobi Y; Namikawa A; Kuranuki S; Matsuura N; Sato M; Igarashi Y; Nakamura T; Oikawa T
    Med Chem; 2011 Jul; 7(4):250-6. PubMed ID: 21568875
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-diabetic properties of Daphniphyllum macropodum fruit and its active compound.
    Koo HJ; Kwak JH; Kang SC
    Biosci Biotechnol Biochem; 2014; 78(8):1392-401. PubMed ID: 25130743
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
    Tjokroprawiro A
    Acta Med Indones; 2006; 38(3):160-6. PubMed ID: 17119268
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) as a Target for Concurrent Management of Diabetes and Obesity-Related Cancer.
    Wang Q; Imam MU; Yida Z; Wang F
    Curr Pharm Des; 2017; 23(25):3677-3688. PubMed ID: 28677503
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Healing the diabetic heart: modulation of cardiometabolic syndrome through peroxisome proliferator activated receptors (PPARs).
    Huang TH; Roufogalis BD
    Curr Mol Pharmacol; 2012 Jun; 5(2):241-7. PubMed ID: 22122453
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons.
    Tenenbaum A; Motro M; Fisman EZ
    Cardiovasc Diabetol; 2005 Sep; 4():14. PubMed ID: 16168052
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential responses of PPARalpha, PPARdelta, and PPARgamma reporter cell lines to selective PPAR synthetic ligands.
    Seimandi M; Lemaire G; Pillon A; Perrin A; Carlavan I; Voegel JJ; Vignon F; Nicolas JC; Balaguer P
    Anal Biochem; 2005 Sep; 344(1):8-15. PubMed ID: 16038868
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The roles of peroxisome proliferator-activated receptors in the metabolic syndrome.
    Mansour M
    Prog Mol Biol Transl Sci; 2014; 121():217-66. PubMed ID: 24373239
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Pathophysiological relevance of peroxisome proliferators activated receptors (PPAR) to joint diseases - the pro and con of agonists].
    Jouzeau JY; Moulin D; Koufany M; Sebillaud S; Bianchi A; Netter P
    J Soc Biol; 2008; 202(4):289-312. PubMed ID: 19094928
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design, synthesis, and biological evaluation of a novel dual peroxisome proliferator-activated receptor alpha/delta agonist for the treatment of diabetic kidney disease through anti-inflammatory mechanisms.
    Liu K; Zhao X; Qi X; Hou DL; Li HB; Gu YH; Xu QL
    Eur J Med Chem; 2021 Jun; 218():113388. PubMed ID: 33784603
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.